Background - Ecubectedin (PM14) is a novel transcriptional inhibitor related to ecteinascidins family...In mice bearing MDA-MB-231, H526 and 22Rv1 tumors, complete tumor remissions were seen in 1/10 (lasting 103 days), 9/10 (lasting 220 days) and 7/10 (lasting 13 days) ecubectedin-treated animals, respectively.Conclusions - Ecubectedin is a novel transcriptional inhibitor that displays potent antiproliferative activity in different human solid cancer models in vitro and in vivo. The drug is currently in clinical development in Phase II trials.

1 year ago

Preclinical

TNFA (Tumor Necrosis Factor-Alpha) • ANXA5 (Annexin A5)

ecubectedin (PM14)

2years

PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=150, Recruiting, PharmaMar | Active, not recruiting --> Recruiting

2 years ago

Enrollment open

BRCA (Breast cancer early onset)

BRCA mutation

ecubectedin (PM14)

over2years

PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=150, Active, not recruiting, PharmaMar | Recruiting --> Active, not recruiting

over 2 years ago

Clinical • Enrollment closed

BRCA (Breast cancer early onset)

BRCA mutation

ecubectedin (PM14)

over2years

PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=150, Recruiting, PharmaMar

over 2 years ago

Clinical • New P1 trial

BRCA (Breast cancer early onset)

BRCA mutation

ecubectedin (PM14)